US6750325B1
(en)
|
1989-12-21 |
2004-06-15 |
Celltech R&D Limited |
CD3 specific recombinant antibody
|
GB8928874D0
(en)
|
1989-12-21 |
1990-02-28 |
Celltech Ltd |
Humanised antibodies
|
US5859205A
(en)
|
1989-12-21 |
1999-01-12 |
Celltech Limited |
Humanised antibodies
|
GB9109645D0
(en)
*
|
1991-05-03 |
1991-06-26 |
Celltech Ltd |
Recombinant antibodies
|
US5994510A
(en)
*
|
1990-12-21 |
1999-11-30 |
Celltech Therapeutics Limited |
Recombinant antibodies specific for TNFα
|
US7192584B2
(en)
|
1991-03-18 |
2007-03-20 |
Centocor, Inc. |
Methods of treating psoriasis with anti-TNF antibodies
|
US5919452A
(en)
*
|
1991-03-18 |
1999-07-06 |
New York University |
Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
|
DK0610201T4
(da)
|
1991-03-18 |
2008-02-04 |
Centocor Inc |
Monoklonale og kimære antistoffer, der er specifikke for human tumornekrosefaktor
|
US5656272A
(en)
*
|
1991-03-18 |
1997-08-12 |
New York University Medical Center |
Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
|
US6277969B1
(en)
|
1991-03-18 |
2001-08-21 |
New York University |
Anti-TNF antibodies and peptides of human tumor necrosis factor
|
US6284471B1
(en)
|
1991-03-18 |
2001-09-04 |
New York University Medical Center |
Anti-TNFa antibodies and assays employing anti-TNFa antibodies
|
IT1254315B
(it)
*
|
1992-03-27 |
1995-09-14 |
Mini Ricerca Scient Tecnolog |
Anticorpi monoclonali anti-idiotipici diretti contro anticorpi anti-tnf.
|
DE69321909T2
(de)
*
|
1992-08-28 |
1999-04-01 |
Bayer Ag |
Verwendung von monoklonalen Anti-TNF-Antikörpern für die Behandlung von bakteriellen Meningitiden
|
US6270766B1
(en)
|
1992-10-08 |
2001-08-07 |
The Kennedy Institute Of Rheumatology |
Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
|
US6863890B1
(en)
|
1993-02-26 |
2005-03-08 |
Advanced Biotherapy, Inc. |
Treatment of AIDS with antibodies to gamma interferon, alpha interferon and TNF-alpha
|
US5888511A
(en)
*
|
1993-02-26 |
1999-03-30 |
Advanced Biotherapy Concepts, Inc. |
Treatment of autoimmune diseases, including AIDS
|
CA2163032C
(en)
*
|
1993-06-03 |
2001-02-06 |
John Landon |
Antibody fragments in therapy
|
CA2097952C
(en)
*
|
1993-06-08 |
2006-03-14 |
Alex D. Romaschin |
Early diagnosis of sepsis utilizing antigen-antibody interactions amplified by whole blood chemiluminescence
|
NZ278607A
(en)
*
|
1994-02-07 |
1999-05-28 |
Knoll Ag |
Use of tnf antagonists for treating disorders involving elevated serum levels of il-6 wherein the serum levels are 500pg/ml or above
|
US5804370A
(en)
*
|
1994-06-08 |
1998-09-08 |
Critichem Medical Products Limited |
Early diagnosis of sepsis utilizing antigen-antibody interactions amplified by whole blood chemiluminescence
|
US6203997B1
(en)
|
1994-06-08 |
2001-03-20 |
Sepsis, Inc. |
Quantitation of analytes in whole blood
|
US6090382A
(en)
|
1996-02-09 |
2000-07-18 |
Basf Aktiengesellschaft |
Human antibodies that bind human TNFα
|
US20140212413A1
(en)
*
|
1995-12-11 |
2014-07-31 |
New York University |
Methods of Treating TNF-alpha-Mediated Diseases Using Chimeric TNF-alpha Antibodies
|
HU228630B1
(en)
|
1996-02-09 |
2013-04-29 |
Abbott Biotech Ltd |
Use of human anti bodies that bind human tnf-alpha and process for inhibiting of human tnf-alpha activity
|
US7608262B2
(en)
|
1996-02-16 |
2009-10-27 |
The Kennedy Institute Of Rheumatology |
Methods of preventing or treating thrombosis with tumor necrosis factor antagonists
|
AU4413097A
(en)
*
|
1996-09-19 |
1998-04-14 |
Centocor Inc. |
Hiv-1 therapy with il-2 and anti-tnf antibody
|
ES2213209T3
(es)
*
|
1996-11-15 |
2004-08-16 |
Kennedy Institute Of Rheumatology |
Supresion de tnfalfa e il-12 en terapia.
|
CA2282501A1
(en)
*
|
1997-02-19 |
1998-08-27 |
Centocor, Inc. |
Sustained drug delivery and compositions useful therefor
|
AU7345798A
(en)
*
|
1997-05-12 |
1998-12-08 |
Kennedy Institute Of Rheumatology, The |
Suppression of tumor necrosis factor alpha and vascular endothelial growth factor in therapy
|
US6159683A
(en)
*
|
1997-12-16 |
2000-12-12 |
Spectral Diagnostics, Inc. |
Method of determining stage of sepsis
|
EP1022027A1
(de)
*
|
1999-01-22 |
2000-07-26 |
Applied Research Systems ARS Holding N.V. |
Antagonisten von Tumornecrosefaktor und ihre Verwendungen gegen Endometriose
|
PT1159003E
(pt)
*
|
1999-03-02 |
2011-02-22 |
Centocor Inc |
Anti-tnf alfa na terapêutica da asma resistente a esteróides
|
US20040220103A1
(en)
|
1999-04-19 |
2004-11-04 |
Immunex Corporation |
Soluble tumor necrosis factor receptor treatment of medical disorders
|
JP4812921B2
(ja)
*
|
2000-04-14 |
2011-11-09 |
田辺三菱製薬株式会社 |
ベーチェット病治療剤
|
UA81743C2
(uk)
|
2000-08-07 |
2008-02-11 |
Центокор, Инк. |
МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
|
EP1379275A4
(de)
*
|
2001-03-14 |
2005-12-21 |
Centocor Inc |
Mit chronisch-obstruktiver lungenkrankheit im zusammenhang stehende, von immunglobulin abgeleitete proteine, zusammensetzungen, verfahren und verwendungen
|
CA2868614A1
(en)
|
2001-06-08 |
2002-12-08 |
Abbott Laboratories (Bermuda) Ltd. |
Methods of administering anti-tnf.alpha. antibodies
|
TWI327597B
(en)
|
2001-08-01 |
2010-07-21 |
Centocor Inc |
Anti-tnf antibodies, compositions, methods and uses
|
CA2466592A1
(en)
*
|
2001-11-12 |
2003-05-22 |
Koen Hellendoorn |
Modified anti-tnf alpha antibody
|
US20030206898A1
(en)
|
2002-04-26 |
2003-11-06 |
Steven Fischkoff |
Use of anti-TNFalpha antibodies and another drug
|
MXPA05000815A
(es)
*
|
2002-07-19 |
2005-04-28 |
Abbott Biotech Ltd |
Tratamiento de trastornos relacionados con tnfa.
|
US20040033228A1
(en)
|
2002-08-16 |
2004-02-19 |
Hans-Juergen Krause |
Formulation of human antibodies for treating TNF-alpha associated disorders
|
MY150740A
(en)
|
2002-10-24 |
2014-02-28 |
Abbvie Biotechnology Ltd |
Low dose methods for treating disorders in which tnf? activity is detrimental
|
WO2004050683A2
(en)
|
2002-12-02 |
2004-06-17 |
Abgenix, Inc. |
Antibodies directed to tumor necrosis factor and uses thereof
|
US7344716B2
(en)
|
2003-05-13 |
2008-03-18 |
Depuy Spine, Inc. |
Transdiscal administration of specific inhibitors of pro-inflammatory cytokines
|
US7553827B2
(en)
|
2003-08-13 |
2009-06-30 |
Depuy Spine, Inc. |
Transdiscal administration of cycline compounds
|
US7429378B2
(en)
|
2003-05-13 |
2008-09-30 |
Depuy Spine, Inc. |
Transdiscal administration of high affinity anti-MMP inhibitors
|
US8273347B2
(en)
|
2003-05-13 |
2012-09-25 |
Depuy Spine, Inc. |
Autologous treatment of degenerated disc with cells
|
US8361467B2
(en)
|
2003-07-30 |
2013-01-29 |
Depuy Spine, Inc. |
Trans-capsular administration of high specificity cytokine inhibitors into orthopedic joints
|
US8895540B2
(en)
|
2003-11-26 |
2014-11-25 |
DePuy Synthes Products, LLC |
Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
|
WO2005082377A1
(ja)
|
2004-03-01 |
2005-09-09 |
Ajinomoto Co., Inc. |
抗ヒトTNF-α抗体活性低下抑制剤
|
EP1733056B1
(de)
|
2004-03-31 |
2013-05-22 |
The General Hospital Corporation |
Verfahren zur bestimmung des ansprechens eines tumors auf behandlungen mit dem epidermalen wachstumsfaktor-rezeptor als target
|
TW201705980A
(zh)
|
2004-04-09 |
2017-02-16 |
艾伯維生物技術有限責任公司 |
用於治療TNFα相關失調症之多重可變劑量療法
|
CN102961746B
(zh)
|
2005-05-16 |
2016-06-15 |
艾伯维生物技术有限公司 |
TNFα抑制剂治疗腐蚀性多关节炎的用途
|
JP2009502195A
(ja)
*
|
2005-08-04 |
2009-01-29 |
セントカー・インコーポレーテツド |
抗TNFα抗体および使用方法
|
JP4861019B2
(ja)
*
|
2006-01-31 |
2012-01-25 |
独立行政法人科学技術振興機構 |
ヒトTNF−αに対する抗体酵素およびその利用
|
CA2911000A1
(en)
|
2006-04-05 |
2007-10-18 |
Min W. Wan |
Antibody purification
|
EP2666472A3
(de)
|
2006-04-10 |
2014-04-02 |
Abbott Biotechnology Ltd |
Anwendungen und Zusammensetzungen zur Behandlung von Psoriasis-Arthritis
|
US9605064B2
(en)
|
2006-04-10 |
2017-03-28 |
Abbvie Biotechnology Ltd |
Methods and compositions for treatment of skin disorders
|
EP2010214A4
(de)
|
2006-04-10 |
2010-06-16 |
Abbott Biotech Ltd |
Verwendung und zusammensetzungen zur behandlung von rheumatoider arthritis
|
BRPI0716762A2
(pt)
|
2006-09-13 |
2013-09-24 |
Abbott Lab |
melhorias da cultura celular
|
AU2008251467B2
(en)
|
2007-05-11 |
2014-07-31 |
The Trustees Of The University Of Pennsylvania |
Methods of treatment of skin ulcers
|
KR101690390B1
(ko)
|
2007-05-11 |
2016-12-27 |
토마스 제퍼슨 유니버시티 |
신경변성 질환 및 장애의 치료 및 예방 방법
|
WO2008154543A2
(en)
|
2007-06-11 |
2008-12-18 |
Abbott Biotechnology Ltd. |
Methods for treating juvenile idiopathic arthritis
|
US8969024B2
(en)
|
2007-08-28 |
2015-03-03 |
Abbvie Biotechnology Ltd |
Compositions and methods comprising binding proteins for adalimumab
|
US8986696B2
(en)
|
2007-12-21 |
2015-03-24 |
Depuy Mitek, Inc. |
Trans-capsular administration of p38 map kinase inhibitors into orthopedic joints
|
KR20100120289A
(ko)
|
2008-01-15 |
2010-11-15 |
애보트 게엠베하 운트 콤파니 카게 |
분말상 단백질 조성물 및 이의 제조 방법
|
US9029508B2
(en)
|
2008-04-29 |
2015-05-12 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
JPWO2009142186A1
(ja)
*
|
2008-05-20 |
2011-09-29 |
株式会社カネカ |
細胞障害性組成物
|
PE20100054A1
(es)
|
2008-06-03 |
2010-03-03 |
Abbott Lab |
Inmunoglobulina con dominio variable dual
|
PE20100092A1
(es)
|
2008-06-03 |
2010-03-12 |
Abbott Lab |
Inmunoglobulina con dominio variable dual y usos de la misma
|
KR20110017431A
(ko)
|
2008-06-10 |
2011-02-21 |
아보트 러보러터리즈 |
신규한 트리사이클릭 화합물
|
RU2011104348A
(ru)
|
2008-07-08 |
2012-08-20 |
Эбботт Лэборетриз (Us) |
Иммуноглобулины с двойным вариабельным доменом против простагландина е2 и их применение
|
US8415291B2
(en)
|
2008-10-31 |
2013-04-09 |
Centocor Ortho Biotech Inc. |
Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
|
JP2009102390A
(ja)
*
|
2009-01-21 |
2009-05-14 |
Mitsubishi Tanabe Pharma Corp |
ベーチェット病治療剤
|
EP2228652A1
(de)
|
2009-03-11 |
2010-09-15 |
Medizinische Universität Wien |
Verbesserung bei der Tumorbehandlung
|
WO2011015916A2
(en)
*
|
2009-08-03 |
2011-02-10 |
Avesthagen Limited |
Vectors and compounds for expression of recombinant infliximab
|
EP3029070A1
(de)
|
2009-08-29 |
2016-06-08 |
AbbVie Inc. |
Therapeutische dll4-bindende proteine
|
AR078651A1
(es)
|
2009-10-15 |
2011-11-23 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
UY32979A
(es)
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
SG181147A1
(en)
|
2009-12-01 |
2012-07-30 |
Abbott Lab |
Novel tricyclic compounds
|
CR20170159A
(es)
|
2009-12-01 |
2017-06-26 |
Abbvie Inc |
Nuevos compuestos tricíclicos
|
JO3417B1
(ar)
|
2010-01-08 |
2019-10-20 |
Regeneron Pharma |
الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
|
CL2010000019A1
(es)
*
|
2010-01-11 |
2010-06-11 |
Univ Chile |
Anticuerpo monoclonal contra el tnf humano y sus fragmentos, secuencias nucleotidicas que lo codifican, vector de expresion y celulas que las contienen, composiciones y kit que comprenden el anticuerpo, uso de los mismos y metodo para su obtencion.
|
US8846397B2
(en)
|
2010-01-20 |
2014-09-30 |
Merck Sharp & Dohme Corp. |
Immunoregulation by anti-ILT5 antibodies and ILT5-binding antibody fragments
|
CA2787783A1
(en)
|
2010-01-20 |
2011-07-28 |
Tolerx, Inc. |
Anti-ilt5 antibodies and ilt5-binding antibody fragments
|
MY160628A
(en)
|
2010-03-02 |
2017-03-15 |
Abbvie Inc |
Therapeutic DLL4 Binding Proteins
|
CN103079594B
(zh)
|
2010-06-03 |
2016-04-13 |
艾伯维生物技术有限公司 |
用于治疗化脓性汗腺炎(hs)的用途和组合物
|
MY160445A
(en)
|
2010-08-03 |
2017-03-15 |
Abbvie Inc |
Dual Variable Domain Immunoglobulins And Uses Thereof
|
US8822663B2
(en)
|
2010-08-06 |
2014-09-02 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
JP2013539364A
(ja)
|
2010-08-26 |
2013-10-24 |
アッヴィ・インコーポレイテッド |
二重可変ドメイン免疫グロブリンおよびその使用
|
HUE058896T2
(hu)
|
2010-10-01 |
2022-09-28 |
Modernatx Inc |
N1-metil-pszeudo-uracilt tartalmazó ribonukleinsavak és azok felhasználásai
|
US8658171B2
(en)
|
2011-02-28 |
2014-02-25 |
Livzon Mabpharm Inc. |
Humanized anti-TNFα antibodies
|
CN102675460B
(zh)
|
2011-02-28 |
2015-08-19 |
珠海市丽珠单抗生物技术有限公司 |
抗肿瘤坏死因子α的人源化抗体
|
US8710200B2
(en)
|
2011-03-31 |
2014-04-29 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids encoding a modified erythropoietin and their expression
|
EP2702077A2
(de)
|
2011-04-27 |
2014-03-05 |
AbbVie Inc. |
Verfahren zur steuerung des galactosylierungsprofil von rekombinant exprimierten proteinen
|
EP2720721B1
(de)
|
2011-06-17 |
2017-08-30 |
President and Fellows of Harvard College |
Frizzled 2 als zielmolekül für therapeutische antikörper bei der behandlung von krebs
|
WO2013003697A1
(en)
|
2011-06-30 |
2013-01-03 |
Trustees Of Boston University |
Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
|
EP2739650A4
(de)
*
|
2011-08-01 |
2015-04-01 |
Avaxia Biologics Inc |
Für humanen tnf spezifischer boviner polyklonaler antikörper
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
RS62993B1
(sr)
|
2011-10-03 |
2022-03-31 |
Modernatx Inc |
Modifikovani nukleozidi, nukleotidi, i nukleinske kiseline, i njihove upotrebe
|
US9943594B2
(en)
|
2011-10-11 |
2018-04-17 |
Sanofi Biotechnology |
Methods for the treatment of rheumatoid arthritis
|
TWI589299B
(zh)
|
2011-10-11 |
2017-07-01 |
再生元醫藥公司 |
用於治療類風濕性關節炎之組成物及其使用方法
|
US9580501B2
(en)
|
2011-12-16 |
2017-02-28 |
Synthon Biopharmaceuticals B.V. |
Anti-TNF alpha monoclonal secretory IgA antibodies and methods for treating inflammatory diseases
|
CN104114572A
(zh)
|
2011-12-16 |
2014-10-22 |
现代治疗公司 |
经修饰的核苷、核苷酸和核酸组合物
|
EP2797955A2
(de)
|
2011-12-30 |
2014-11-05 |
AbbVie Inc. |
Immunglobuline mit zweifacher variabler domäne gegen il-13 und/oder il-17
|
JP2012092147A
(ja)
*
|
2012-02-07 |
2012-05-17 |
Mitsubishi Tanabe Pharma Corp |
ベーチェット病治療剤
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
US9303079B2
(en)
|
2012-04-02 |
2016-04-05 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
DE18200782T1
(de)
|
2012-04-02 |
2021-10-21 |
Modernatx, Inc. |
Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
US9067990B2
(en)
|
2013-03-14 |
2015-06-30 |
Abbvie, Inc. |
Protein purification using displacement chromatography
|
US9181572B2
(en)
|
2012-04-20 |
2015-11-10 |
Abbvie, Inc. |
Methods to modulate lysine variant distribution
|
US9334319B2
(en)
|
2012-04-20 |
2016-05-10 |
Abbvie Inc. |
Low acidic species compositions
|
US9249182B2
(en)
|
2012-05-24 |
2016-02-02 |
Abbvie, Inc. |
Purification of antibodies using hydrophobic interaction chromatography
|
US9512214B2
(en)
|
2012-09-02 |
2016-12-06 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
KR20150043523A
(ko)
|
2012-09-02 |
2015-04-22 |
애브비 인코포레이티드 |
단백질 불균일성의 제어 방법
|
KR20210111353A
(ko)
|
2012-11-01 |
2021-09-10 |
애브비 인코포레이티드 |
항-vegf/dll4 이원 가변 도메인 면역글로불린 및 이의 용도
|
EP4074834A1
(de)
|
2012-11-26 |
2022-10-19 |
ModernaTX, Inc. |
Am kettenende modifizierte rna
|
SG11201507230PA
(en)
|
2013-03-12 |
2015-10-29 |
Abbvie Inc |
Human antibodies that bind human tnf-alpha and methods of preparing the same
|
US9499614B2
(en)
|
2013-03-14 |
2016-11-22 |
Abbvie Inc. |
Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
|
US9017687B1
(en)
|
2013-10-18 |
2015-04-28 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same using displacement chromatography
|
US8921526B2
(en)
|
2013-03-14 |
2014-12-30 |
Abbvie, Inc. |
Mutated anti-TNFα antibodies and methods of their use
|
EP2970459A2
(de)
|
2013-03-15 |
2016-01-20 |
AbbVie Inc. |
Gegen il-1beta und il-17 gerichtete duale spezifische bindungsproteine
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
SG11201507577RA
(en)
|
2013-03-15 |
2015-10-29 |
Janssen Biotech Inc |
Manufacturing methods to control c-terminal lysine, galactose and sialic acid content in recombinant proteins
|
WO2014160871A2
(en)
|
2013-03-27 |
2014-10-02 |
The General Hospital Corporation |
Methods and agents for treating alzheimer's disease
|
EP3052106A4
(de)
|
2013-09-30 |
2017-07-19 |
ModernaTX, Inc. |
Polynukleotide zur codierung immunmodulierender polypeptide
|
MX2016004249A
(es)
|
2013-10-03 |
2016-11-08 |
Moderna Therapeutics Inc |
Polinulcleotidos que codifican el receptor de lipoproteina de baja densidad.
|
US9598667B2
(en)
|
2013-10-04 |
2017-03-21 |
Abbvie Inc. |
Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
|
US8946395B1
(en)
|
2013-10-18 |
2015-02-03 |
Abbvie Inc. |
Purification of proteins using hydrophobic interaction chromatography
|
US9085618B2
(en)
|
2013-10-18 |
2015-07-21 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same
|
US9181337B2
(en)
|
2013-10-18 |
2015-11-10 |
Abbvie, Inc. |
Modulated lysine variant species compositions and methods for producing and using the same
|
US20150139988A1
(en)
|
2013-11-15 |
2015-05-21 |
Abbvie, Inc. |
Glycoengineered binding protein compositions
|
JP5797728B2
(ja)
*
|
2013-12-20 |
2015-10-21 |
田辺三菱製薬株式会社 |
ベーチェット病治療剤
|
KR101921552B1
(ko)
|
2014-03-10 |
2018-11-23 |
리히터 게데온 닐트. |
사전 세정 단계를 이용하는 면역글로불린 정제
|
KR102617137B1
(ko)
|
2014-09-15 |
2023-12-27 |
칠드런'즈 메디컬 센터 코포레이션 |
히스톤 h3-리신 트리메틸화를 제거함으로써 체세포 핵 이식(scnt) 효율을 증가시키는 방법 및 조성물
|
US10093733B2
(en)
|
2014-12-11 |
2018-10-09 |
Abbvie Inc. |
LRP-8 binding dual variable domain immunoglobulin proteins
|
EP3078675A1
(de)
|
2015-04-10 |
2016-10-12 |
Ares Trading S.A. |
Induktionsdosierschema zur behandlung von krankheiten die von tnf alpha verursacht sind
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗vegf、pdgf及/或其受體之結合蛋白
|
HU231463B1
(hu)
|
2015-08-04 |
2024-01-28 |
Richter Gedeon Nyrt. |
Módszer rekombináns proteinek galaktóz tartalmának növelésére
|
US11512092B2
(en)
|
2015-10-16 |
2022-11-29 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
US10550126B2
(en)
|
2015-10-16 |
2020-02-04 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
EP3362455A1
(de)
|
2015-10-16 |
2018-08-22 |
AbbVie Inc. |
Verfahren zur herstellung von (3s,4r)-3-ethyl-4-(3h-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluorethyl)pyrrolidin-1-carboxamid und festkörperformen davon
|
US11365198B2
(en)
|
2015-10-16 |
2022-06-21 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
US11524964B2
(en)
|
2015-10-16 |
2022-12-13 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
US11780848B2
(en)
|
2015-10-16 |
2023-10-10 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
|
US10465003B2
(en)
|
2016-02-05 |
2019-11-05 |
Janssen Biotech, Inc. |
Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
|
JP7177777B2
(ja)
|
2017-01-11 |
2022-11-24 |
セルトリオン, インク. |
安定した液体製剤
|
KR20240038146A
(ko)
|
2017-01-30 |
2024-03-22 |
얀센 바이오테크 인코포레이티드 |
활성 건선성 관절염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
|
CN110418652A
(zh)
|
2017-02-07 |
2019-11-05 |
詹森生物科技公司 |
用于治疗活动性强直性脊柱炎的抗tnf抗体、组合物和方法
|
US11319375B2
(en)
|
2018-08-29 |
2022-05-03 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for treating subjects having rheumatoid arthritis
|
HUP1800376A2
(hu)
|
2018-11-07 |
2020-05-28 |
Richter Gedeon Nyrt |
Sejttenyészetben elõállított rekombináns glikoprotein glikozilációs-mintázatának megváltoztatására szolgáló módszer
|
CN114206442A
(zh)
|
2019-01-31 |
2022-03-18 |
赛诺菲生物技术公司 |
用于治疗幼年特发性关节炎的抗il-6受体抗体
|
HU231498B1
(hu)
|
2019-04-04 |
2024-05-28 |
Richter Gedeon Nyrt |
Immunglobulinok affinitás kromatográfiájának fejlesztése kötést megelőző flokkulálás alkalmazásával
|
MX2021014302A
(es)
|
2019-05-23 |
2022-01-04 |
Janssen Biotech Inc |
Metodo para tratar la enfermedad inflamatoria del intestino con una terapia de combinacion de anticuerpos contra il-23 y tnf alfa.
|
JP2023554200A
(ja)
|
2020-12-09 |
2023-12-26 |
エイチケー イノ.エヌ コーポレーション |
抗OX40L抗体、抗OX40L及び抗TNFαの二重特異性抗体、並びにこれらの用途
|
WO2024054934A1
(en)
|
2022-09-07 |
2024-03-14 |
Mdx Management Llc |
Shp-1 inhibitors for treating cancer
|
WO2024097804A1
(en)
|
2022-11-02 |
2024-05-10 |
Mdx Management Llc |
Combination of a tyrosine kinase inhibitor and a pro-inflammatory agent for treating cancer
|